Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects

Last updated: July 28, 2014
Sponsor: Alcon Research
Overall Status: Completed

Phase

3

Condition

Eye Disorders/infections

Allergies & Asthma

Allergy (Pediatric)

Treatment

N/A

Clinical Study ID

NCT00987272
C-09-044
  • Ages > 18
  • All Genders

Study Summary

The purpose of the study is to demonstrate safety and efficacy of Olopatadine 0.2% compared to its vehicle in Japanese subjects in the treatment of acute allergen-mediated conjunctivitis using the conjunctival allergen challenge (CAC) test.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Japanese ethnicity.

  • Seasonal Allergic Conjunctivitis--asymptomatic.

  • Other protocol-defined inclusion criteria may apply.

Exclusion

Exclusion Criteria:

  • Manifest signs and symptoms of clinically active allergic conjunctivitis in either eye (>1 for redness in any of the 3 vessels beds - conjunctival, episcleral, ciliary - oritching >0) at the start of any visit.

  • Other protocol-defined exclusion criteria may apply.

Study Design

Total Participants: 267
Study Start date:
October 01, 2009
Estimated Completion Date:
November 30, 2009

Connect with a study center

  • Contact Alcon Call Center For Trial Locations

    Fort Worth, Texas 76134
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.